News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO , Jan. 26, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,183,432 shares of Series A-1 Convertible Preferred Stock to a
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO , Jan. 26, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,183,432 shares of Series A-1 Convertible Preferred Stock to a
Toggle Summary Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , Jan. 14, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO , Jan. 14, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Toggle Summary Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
SAN DIEGO , Dec. 07, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
SAN DIEGO , Dec. 07, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today announced the resubmission of the Company’s New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for its Epinephrine Pre-filled Syringe (“PFS”)
Toggle Summary Adamis Pharmaceuticals Provides Regulatory Update on Its Epinephrine Pre-Filled Syringe
SAN DIEGO , Aug. 06, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today provided an update on the status of and guidance for the resubmission of the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”) product
Adamis Pharmaceuticals Provides Regulatory Update on Its Epinephrine Pre-Filled Syringe
SAN DIEGO , Aug. 06, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today provided an update on the status of and guidance for the resubmission of the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”) product
Toggle Summary Adamis Pharmaceuticals Announces Key Additions to Its Commercial Sales Team
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for
Adamis Pharmaceuticals Announces Key Additions to Its Commercial Sales Team
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for
Toggle Summary Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO, March 27, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP
Adamis Pharmaceuticals Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA
SAN DIEGO, March 27, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP
Toggle Summary Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis'
Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis'
Toggle Summary Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results for Its Beclomethasone Dipropionate HFA Product
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
Adamis Pharmaceuticals Announces Positive Pharmacokinetic Study Results for Its Beclomethasone Dipropionate HFA Product
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
Toggle Summary Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Toggle Summary Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
Toggle Summary Adamis Pharmaceuticals To Present at Two Upcoming Conferences
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
Adamis Pharmaceuticals To Present at Two Upcoming Conferences
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation  ADMP,  -0.64%  today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
Toggle Summary Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
Toggle Summary Adamis Pharmaceuticals Announces Appointment of New Members to its Board of Directors
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
Adamis Pharmaceuticals Announces Appointment of New Members to its Board of Directors
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
Toggle Summary Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare
Adamis Pharmaceuticals Announces Private Placement
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare
Toggle Summary FDA Accepts for Review Adamis’ New Drug Application for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - Jul 29, 2014) -    Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
FDA Accepts for Review Adamis’ New Drug Application for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - Jul 29, 2014) -    Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
Toggle Summary Adamis Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th  Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
Adamis Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th  Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
Toggle Summary Adamis CEO Dr. Dennis J. Carlo to Present at the LD Micro Invitational
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
Adamis CEO Dr. Dennis J. Carlo to Present at the LD Micro Invitational
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
Toggle Summary Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
Toggle Summary Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
Toggle Summary Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
Toggle Summary Adamis Pharmaceuticals Announces Completion of Acquisition
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
Adamis Pharmaceuticals Announces Completion of Acquisition
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ :  ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
Toggle Summary Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
San Diego, California - December 18, 2013  - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
San Diego, California - December 18, 2013  - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
Toggle Summary Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are
Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are